Sebastiano Buti
University of Parma
CancerInternal medicineSurgeryOncologyRetrospective cohort studyAdverse effectLung cancerChemotherapyRenal cell carcinomaCarcinomaImmunotherapySunitinibNivolumabNephrectomyKidney cancerIn patientCancer researchClinical trialMedicineImmune system
240Publications
24H-index
1,869Citations
Publications 241
Newest
#1Fabiana PerroneH-Index: 8
#2Maurizio BalbiH-Index: 3
Last. Melissa BersanelliH-Index: 19
view all 0 authors...
Differential diagnosis of COVID-19 at the chest computed tomography scan: A review with special focus on cancer patients
Source
#1Alessio Cortellini (University of L'Aquila)H-Index: 18
#2Melissa Bersanelli (University of Parma)H-Index: 19
Last. Sebastiano Buti (University of Parma)H-Index: 24
view all 0 authors...
Source
#1Orazio CaffoH-Index: 36
#2Cinzia Ortega (UNITO: University of Turin)H-Index: 23
Last. Gaetano FacchiniH-Index: 28
view all 41 authors...
Abstract null null Background null Pre-clinical data suggest that docetaxel and enzalutamide interfere with androgen receptor translocation and signalling. The aim of this study is to assess the efficacy of their concurrent administration in the first-line treatment for metastatic castration-resistant prostate cancer (mCRPC). null null null Methods null In this open-label, randomised, phase II trial, previously untreated mCRPC patients were randomised 1:1 to receive eight 21-d courses of docetax...
Source
#1Matteo SantoniH-Index: 44
#2Francesco MassariH-Index: 41
Last. Roberto Iacovelli (Agostino Gemelli University Polyclinic)H-Index: 32
view all 21 authors...
BACKGROUND Renal cell carcinoma with sarcomatoid differentiation is a highly aggressive form of kidney cancer. OBJECTIVE We aimed to analyze the outcomes of patients treated with cabozantinib for metastatic renal cell carcinoma with sarcomatoid features. METHODS We retrospectively collected data from 16 worldwide centers. Overall survival and progression-free survival were analyzed using Kaplan-Meier curves. Cox proportional models were used for univariate and multivariate analyses. RESULTS We c...
Source
#1Daniele Santini (Università Campus Bio-Medico)H-Index: 74
#2Tea Zeppola (Università Campus Bio-Medico)H-Index: 9
Last. Vincenzo Adamo (UNIME: University of Messina)H-Index: 28
view all 48 authors...
BACKGROUND The favourable safety profile and the increasing confidence with immune checkpoint inhibitors (ICIs) might have boosted their prescription in frail patients with short life expectancies, who usually are not treated with standard chemotherapy. METHODS The present analysis aims to describe clinicians' attitudes towards ICIs administration during late stages of life within a multicenter cohort of advanced cancer patients treated with single agent PD-1/PD-L1 checkpoint inhibitors in Italy...
Source
#1Melissa Bersanelli (University of Parma)H-Index: 19
#2Sebastiano Buti (University of Parma)H-Index: 24
Last. Clara Indira DadomoH-Index: 1
view all 22 authors...
Source
#1Sebastiano ButiH-Index: 24
#2Melissa BersanelliH-Index: 19
Last. Alessio Cortellini (University of L'Aquila)H-Index: 18
view all 61 authors...
BACKGROUND We previously demonstrated the cumulative poor prognostic role of concomitant medications on the clinical outcome of patients with advanced cancer treated with immune checkpoint inhibitors, creating and validating a drug-based prognostic score to be calculated before immunotherapy initiation in patients with advanced solid tumours. This 'drug score' was calculated assigning score 1 for each between proton-pump inhibitor and antibiotic administration until a month before cancer therapy...
Source
Source
Source
Source